These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 12204499)

  • 21. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
    Unger T
    Am J Cardiol; 2003 May; 91(10A):28G-34G. PubMed ID: 12781906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the Heart Outcomes Prevention Evaluation (HOPE) study.
    Carroll CA; Coen MM; Rymer MM
    Clin Ther; 2003 Apr; 25(4):1248-61. PubMed ID: 12809971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telmisartan, ramipril, or both in patients at high risk for vascular events.
    ; Yusuf S; Teo KK; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P; Anderson C
    N Engl J Med; 2008 Apr; 358(15):1547-59. PubMed ID: 18378520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators.
    Cleland JG; Erhardt L; Murray G; Hall AS; Ball SG
    Eur Heart J; 1997 Jan; 18(1):41-51. PubMed ID: 9049514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial.
    Dagenais GR; Yi Q; Lonn E; Sleight P; Ostergren J; Yusuf S;
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):75-81. PubMed ID: 15703510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients.
    Anderson VR; Perry CM; Robinson DM
    Am J Cardiovasc Drugs; 2006; 6(6):417-32. PubMed ID: 17192135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are ACE-inhibitors or ARB's still needed for cardiovascular prevention in high risk patients? Insights from profess and transcend.
    Van Mieghem W; Billiouw JM; Brohet C; Dupont AG; Gazagnes MD; Heller F; Krzesinski JM; Missault L; Persu A; Piérard L; Rottiers R; Vanhooren G; Vervaet P; Herman AG
    Acta Clin Belg; 2010; 65(2):107-14. PubMed ID: 20491360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diabetes and the HOPE study: implications for macrovascular and microvascular disease.
    Gerstein HC
    Int J Clin Pract Suppl; 2001 Jan; (117):8-12. PubMed ID: 11715357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study.
    Dagenais GR; Yusuf S; Bourassa MG; Yi Q; Bosch J; Lonn EM; Kouz S; Grover J;
    Circulation; 2001 Jul; 104(5):522-6. PubMed ID: 11479247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.
    Mann JF; Gerstein HC; Pogue J; Bosch J; Yusuf S
    Ann Intern Med; 2001 Apr; 134(8):629-36. PubMed ID: 11304102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?
    Sica DA
    Curr Opin Nephrol Hypertens; 2001 Sep; 10(5):597-601. PubMed ID: 11496052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended follow-up of patients randomly assigned in the Angiotensin-converting enzyme inhibition Post-Revascularization Study (APRES).
    Kjøller-Hansen L; Steffensen R; Grande P
    Am Heart J; 2004 Sep; 148(3):475-80. PubMed ID: 15389235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.
    Dagenais GR; Pogue J; Fox K; Simoons ML; Yusuf S
    Lancet; 2006 Aug; 368(9535):581-8. PubMed ID: 16905022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Ten years after publishing results from The Heart Outcomes Prevention Evaluation Study--HOPE: implications on treatment with angiotensin converting enzyme inhibitors in clinical practice].
    Pocanić D
    Lijec Vjesn; 2011; 133(1-2):69-71. PubMed ID: 21644282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - A network meta-analysis.
    Ricci F; Di Castelnuovo A; Savarese G; Perrone Filardi P; De Caterina R
    Int J Cardiol; 2016 Aug; 217():128-34. PubMed ID: 27179902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin-converting enzyme inhibitor therapy affects left ventricular mass in patients with ejection fraction > 40% after acute myocardial infarction.
    Johnson DB; Foster RE; Barilla F; Blackwell GG; Roney M; Stanley AW; Kirk K; Orr RA; van der Geest RJ; Reiber JH; Dell'Italia LJ
    J Am Coll Cardiol; 1997 Jan; 29(1):49-54. PubMed ID: 8996294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The HOPE Study. What does it contribute to general practice?].
    Mann J; Sleight P
    MMW Fortschr Med; 2000 Nov; 142(47):28-32. PubMed ID: 11143776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.
    Mathew J; Sleight P; Lonn E; Johnstone D; Pogue J; Yi Q; Bosch J; Sussex B; Probstfield J; Yusuf S;
    Circulation; 2001 Oct; 104(14):1615-21. PubMed ID: 11581138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ramipril in the treatment of vascular diseases.
    Rokoss MJ; Teo KK
    Expert Opin Pharmacother; 2005 Sep; 6(11):1911-9. PubMed ID: 16144510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of ramipril on the circadian periodicity of acute myocardial infarction.
    Dagenais GR; Pogue J; Teo KK; Lonn EM; Yusuf S;
    Am J Cardiol; 2006 Sep; 98(6):758-60. PubMed ID: 16950179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.